January #55 : Next Up...The lowdown on what’s inside the pipeline - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Work 2000

Take This Job & Love it!

POZ Work

Editor's Letter

Mailbox

Glaxo Makes a Deal

For Whom the Nobel Tolls

Homesick Blues

NEG/POZ

"Dutch" Treat

Eye of the Beholder

Shout Out

LA Women

Missing Persons Report

Catching Up With Michael Johnston

Milestones

Oink, Oink

A Define Mess

Do Ask, Do Tell

Primary Colors

A Modest Proposal

Portrait of the Artist as a Sex Bomb

Play It As It Lays

Beginner's Luck

Follow Your Heart

Next Up...The lowdown on what’s inside the pipeline

Stool's Gold

Comfort Zone

Wart's Up, Nurse?

Herb of the Month

Cancer Answers

Watch Your Hep

Boys' Night Out



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

January 2000

Next Up...The lowdown on what’s inside the pipeline

by Tim Horn

Brand Name: To be announced
Generic Name: Tipranavir
Company: Pharmacia & Upjohn
For: HIV
Class: Protease Inhibitor (PI)
Status: Phase II trials under way
Standard Treatment: Highly active antiretroviral therapy (HAART)
Notes: Designed with resistance
in mind. A test-tube study found tipranavir to be 90 percent effective against HIV strains resistant to three or more PIs. Information about dosing and side effects to be determined.
From the gut of PWA Stephen Gendin: “I’m skeptical of claims of unique-resistance profiles—they usually don’t pan out. Tipranavir’s long-term toxicities and dosing are the drug’s most promising aspects, though both are still unclear.”

Brand Name: Coactinon
Generic Name: Emivirine
Company: Triangle Pharmaceuticals
For: HIV
Class: NNRTI
Status: Phase I/II trials under way
Standard Treatment: HAART
Notes: A non-nucleoside reverse transcriptase inhibitor (NNRTI) similar to nevirapine (Viramune), delavirdine (Rescriptor) and efavirenz (Sustiva). Twice-daily dosing is the plan, and information about side effects is pending.
From the gut of PWA Stephen Gendin: “What’s so exciting about an NNRTI with an overlapping resistance profile? It’s only useful to the NNRTI-naive, and there’s no evidence that it’s better than the NNRTIs already available.”

Brand Name: To be announced
Generic Name: T-20 (Pentafuside)
Company: Trimeris
For: HIV
Class: Fusion Inhibitor
Status: Phase II trials under way
Standard Treatment: HAART
Notes: This new class of anti-HIV drug prevents the virus from attaching to CD4 cells at one particular site. No major side effects reported, but dosing is a hassle: T-20 is not effective if taken orally, so twice-daily injections are needed.
From the gut of PWA Stephen Gendin: Finally, a drug that operates in a unique way! This drug is important for people who’ve run through all other drug options. For those in need of new therapies, self-injection is the least of their problems.”

Brand Name: Pegasys
Generic Name: Pegylated Interferon
Company: Hoffman LaRoche
For: Hepatitis C (HCV)
Class: Interferon
Status: Phase III trials under way; approvals pending
Standard Treatment: Robertron (ribavirin and standard interferon)
Notes: A new formulation of an old drug, pegylated interferon can be taken just once a week. In two clinical trials—neither enrolled HIVers—the drug was more effective than standard interferon in combating hepatitis C.
From the gut of PWA Stephen Gendin: “More convenient and less toxic than the standard treatment, this drug will be very popular. But as with anti-HIV meds, it still needs to be teamed with other drugs to control hepatitis C.”




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.